Market Cap : 158.59 B | Enterprise Value : 189.83 B | PE Ratio : 24.67 | PB Ratio : 4.86 |
---|
NYSE:BMY has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NYSE:BMY has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Bristol-Myers Squibb Co's share price is $74.335. Bristol-Myers Squibb Co's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2022 was $21.49. Hence, Bristol-Myers Squibb Co's PS Ratio for today is 3.46.
Warning Sign:
Bristol-Myers Squibb Co stock PS Ratio (=3.49) is close to 2-year high of 3.71
The historical rank and industry rank for Bristol-Myers Squibb Co's PS Ratio or its related term are showing as below:
During the past 13 years, Bristol-Myers Squibb Co's highest PS Ratio was 7.25. The lowest was 2.39. And the median was 4.18.
BMY's PS Ratio is ranked worse thanBristol-Myers Squibb Co's Revenue per Sharefor the three months ended in Jun. 2022 was $5.53. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2022 was $21.49.
During the past 12 months, the average Revenue per Share Growth Rate of Bristol-Myers Squibb Co was 9.60% per year. During the past 3 years, the average Revenue per Share Growth Rate was 14.40% per year. During the past 5 years, the average Revenue per Share Growth Rate was 12.80% per year. During the past 10 years, the average Revenue per Share Growth Rate was 6.80% per year.
During the past 13 years, Bristol-Myers Squibb Co's highest 3-Year average Revenue per Share Growth Rate was 14.40% per year. The lowest was -8.40% per year. And the median was 3.90% per year.
The historical data trend for Bristol-Myers Squibb Co's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's PS Ratio distribution charts can be found below:
* The bar in red indicates where Bristol-Myers Squibb Co's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Bristol-Myers Squibb Co's PS Ratio for today is calculated as
PS Ratio | = | Share Price | / | Revenue per Share (TTM) |
= | 74.335 | / | 21.492 | |
= | 3.46 |
Bristol-Myers Squibb Co's Share Price of today is $74.335.
Bristol-Myers Squibb Co's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $21.49.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
PS Ratio | = | Market Cap | / | Revenue |
The Revenue here is for the trailing 12 months.
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Thank you for viewing the detailed overview of Bristol-Myers Squibb Co's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Greenlees Sharon | officer: SVP & Controller | BRISTOL MYERS SQUIBB ROUTE 206 & PROVINCE LINE ROAD PRINCETON NJ 08543 |
Shanahan Karin | officer: EVP, Glob. Prod. Dev. & Supply | BRISTOL MYERS SQUIBB ROUTE 206 & PROVINCE LINE ROAD PRINCETON NJ 08543 |
Meyers Gregory Scott | officer: EVP, Chief Digital & Tech Off. | BRISTOL MYERS SQUIBB ROUTE 206 & PROVINCE LINE ROAD PRINCETON NJ 08543 |
Weese Michelle | officer: EVP, Corporate Affairs | BRISTOL MYERS SQUIBB ROUTE 206 & PROVINCE LINE ROAD PRINCETON NJ 08543 |
Hidalgo Medina Manuel | director | BRISTOL MYERS SQUIBB 430 E. 29TH STREET, 14TH FLOOR NEW YORK NY 10016 |
Rice Derica W | director | 1000 NICOLLET MALL TPS-3155 MINNEAPOLIS MN 55403 |
Price Paula A | director | ONE CVS DRIVE WOONSOCKET RI 02895 |
Mily Elizabeth | officer: EVP, Strategy & BD | BRISTOL-MYERS SQUIBB COMPANY ROUTE 206 & PROVENCE LINE ROAD PRINCETON NJ 08540 |
Metcalfe Kathryn | officer: EVP, Corporate Affairs | BRISTOL-MYERS SQUIBB COMPANY ROUTE 206 & PROVINCE LINE ROAD PRINCETON NJ 08543 |
Vessey Rupert | officer: Pres., Research & Early Dev. | C/O CELGENE CORPORATION 86 MORRIS AVENUE SUMMIT NJ 07901 |
Elkins David V | officer: EVP, Chief Financial Officer | C/O BECTON, DICKINSON AND COMPANY 1 BECTON DRIVE FRANKLIN LAKES NJ 07417 |
Bonney Michael W | director | 65 HAYDEN AVE LEXINGTON MA 02421 |
Yale Phyllis R | director | |
Ahmed Nadim | officer: President, Hematology | C/O CELGENE CORPORATION 86 MORRIS AVENUE SUMMIT NJ 07901 |
Haller Julia A | director | C/O CELGENE CORPORATION 86 MORRIS AVENUE SUMMIT NJ 07901 |
Other Sources
By Zacks 2022-03-28
By Zacks 2022-04-05
By Zacks 2022-03-16
By Zacks 2022-03-25
By Zacks 2022-03-30
By Fool 2022-03-30
By Fool 2022-03-31
By Zacks 2022-03-21
By Zacks 2022-03-22
By Zacks 2022-04-05
By Zacks 2022-03-29
By Zacks 2022-04-05
By Zacks 2022-03-28
By Zacks 2022-03-30